Trial record 7 of 28 for:    Open Studies | "Bronchitis, Chronic"

Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Royal Brompton & Harefield NHS Foundation Trust.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Medical Research Council
The Hillingdon Hospitals NHS Foundation Trust
West Hertfordshire Hospitals NHS Trust
Information provided by (Responsible Party):
Royal Brompton & Harefield NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01507415
First received: January 6, 2012
Last updated: NA
Last verified: January 2012
History: No changes posted
  Purpose

This study aims to evaluate simple tests of physical function in hospitalised patients with chronic obstructive pulmonary disease (COPD) and to assess whether they can predict future hospital readmission. The Short Physical Performance Battery (SPPB) is a simple test of standing balance, usual walking speed (4-metre gait speed) and ability to stand from a chair, which reflects global physical functioning and frailty.

We hypothesise that the SPPB or 4-metre gait speed can predict future hospital readmissions.


Condition
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Lung Diseases
Lung Diseases, Obstructive
Bronchitis, Chronic
Pulmonary Emphysema
Disease Progression

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?

Resource links provided by NLM:


Further study details as provided by Royal Brompton & Harefield NHS Foundation Trust:

Primary Outcome Measures:
  • Hospital readmission rate [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Hospital readmission rate [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Time to first hospital readmission [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Hospital Bed days [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Whole blood, plasma and serum.


Estimated Enrollment: 225
Study Start Date: November 2011
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Exacerbation
Patients with Chronic Obstructive Pulmonary Disease (COPD)

  Eligibility

Ages Eligible for Study:   35 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Any patient hospitalised with an acute exacerbation of COPD. Cohorts will be recruited from local District General Hospitals with Acute Admissions Units and Accident & Emergency Departments.

Criteria

Inclusion Criteria:

  • Hospital admission with an exacerbation of COPD
  • Must have capacity to consent
  • Able to walk

Exclusion Criteria:

  • Co-morbibities that limit walking ability
  • Co-morbidities that make walking unsafe
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01507415

Contacts
Contact: Samantha SC Kon, BSc MRCP 01895 823 737 ext 5021 lungresearch@rbht.nhs.uk
Contact: William DC Man, MRCP PhD 01895 828 851 research@williamman.co.uk

Locations
United Kingdom
Hillingdon Hospital Recruiting
Uxbridge, United Kingdom, UB8 3NN
Contact: Samantha SC Kon, BSc MRCP    01895 823 737 ext 5021    lungresearch@rbht.nhs.uk   
Watford General Hospital Not yet recruiting
Watford, United Kingdom, WD18 0HB
Contact: Samantha SC Kon, BSc MRCP    01895 823 737 ext 5021    lungresearch@rbht.nhs.uk   
Sponsors and Collaborators
Royal Brompton & Harefield NHS Foundation Trust
Medical Research Council
The Hillingdon Hospitals NHS Foundation Trust
West Hertfordshire Hospitals NHS Trust
Investigators
Principal Investigator: William DC Man, MRCP PhD NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust
  More Information

Publications:
Responsible Party: Royal Brompton & Harefield NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT01507415     History of Changes
Other Study ID Numbers: 2011LF015H
Study First Received: January 6, 2012
Last Updated: January 6, 2012
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Royal Brompton & Harefield NHS Foundation Trust:
Cohort Studies
Longitudinal Studies
Patient Readmission
Hospitalization
Disability Evaluation

Additional relevant MeSH terms:
Bronchitis, Chronic
Bronchitis
Chronic Disease
Emphysema
Pulmonary Emphysema
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Disease Progression
Lung Diseases, Obstructive
Bronchial Diseases
Respiratory Tract Infections
Disease Attributes
Pathologic Processes

ClinicalTrials.gov processed this record on August 28, 2014